• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    H

    Hyogo Brain and Heart Center

    EST. 1981
    602论文总数
    2.2万引用总数

    论文量&引用量时间轴

    机构学者

    论文(602)

    年份
    起
    –
    止
    排序
    1Clinical Outcomes of Drug-Coated Balloon Following Directional Coronary Atherectomy in Acute Vs Chronic Coronary Syndrome.
    Masayoshi Fujii,Hiroyuki Yamamoto,Takahiro Sawada,Yoshinori Yasaka,Kenzo Uzu,Taishi Miyata, Tomohiro Inoue,Tomofumi Takaya
    2026JACC Asia(2026)
    引用
    AI阅读
    加入学术空间
    2Rationale and Design of the ESPIAL Trial ― A Prospective, Randomized, Exploratory Study to Evaluate the Effect of Esaxerenone on Reduction of Urinary Albumin to Creatinine Ratio in Hypertensive Patients Concomitant with Heart Failure and Albuminuria ―
    Shinichiro Suna,Yuki Matsumoto, Katsuyuki Niki,Hiroshi Asanuma,Yoshiharu Higuchi,Yoshio Yasumura,Takahiko Kawarabayashi, Masahiro Izumi,Yoshitaka Okuhara, Shinji Hasegawa,Akiko Goda,Yasunori Ueda,

    Background:Hypertension and coronary artery disease (CAD) are predominant factors of heart failure (HF). The American College of Cardiology/American Heart Association and the Japanese Circulation Society/Japanese Heart Failure Society stages of HF emphasize the development and progression of disease, and advanced stages and progression are associated with reduced survival. In patients with new-onset or worsening HF, albuminuria is consistently associated with clinical and circulating biomarkers of congestion. Esaxerenone is an oral, non-steroidal, selective mineralocorticoid receptor antagonist. It has not been elucidated whether esaxerenone reduces the urinary albumin-to-creatinine ratio (UACR) in hypertensive patients concomitant with HF and albuminuria. Methods and Results:The ESPIAL trial (jRCTs 051210066) is a multicenter, randomized, open-label, active-controlled, parallel-group, exploratory, investigator-initiated clinical study to evaluate whether esaxerenone reduces UACR in hypertensive patients concomitant with HF and albuminuria. This study enrolled hypertensive patients concomitant with HF and albuminuria. The patients were randomized to an esaxerenone group or an amlodipine group in a 1 : 1 ratio. The primary outcome was the ratio of UACR before treatment and 24 weeks after treatment. Conclusions:The ESPIAL trial evaluates the effect of esaxerenone on reduction of UACR in hypertensive patients concomitant with HF and albuminuria.

    2025Circulation reports(2025)
    引用
    AI阅读
    加入学术空间
    3Differential Diagnosis of MCI with Lewy Bodies and MCI Due to Alzheimer's Disease by Visual Assessment of Occipital Hypoperfusion on SPECT Images.
    Takashi Nakata,Kenichi Shimada, Akiko Iba,Haruhiko Oda,Akira Terashima,Yutaka Koide,Ryota Kawasaki,Takahiro Yamada,Kazunari Ishii

    Purpose Predicting progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) or dementia with Lewy bodies (DLB) is important. We evaluated morphological and functional differences between MCI with Lewy bodies (MCI-LB) and MCI due to AD (MCI-AD), and a method for differentiating between these conditions using brain MRI and brain perfusion SPECT. Methods A continuous series of 101 subjects, who had visited our memory clinic and met the definition of MCI, were enrolled retrospectively. They were consisted of 60 MCI-LB and 41 MCI-AD subjects. Relative cerebral blood flow (rCBF) on SPECT images and relative brain atrophy on MRI images were evaluated. We performed voxel-based analysis and visually inspected brain perfusion SPECT images for regional brain atrophy, occipital hypoperfusion and the cingulate island sign (CIS), for differential diagnosis of MCI-LB and MCI-AD. Results MRI showed no significant differences in regional atrophy between the MCI-LB and MCI-AD groups. In MCI-LB subjects, occipital rCBF was significantly decreased compared with MCI-AD subjects ( p < 0.01, family wise error [FWE]-corrected). Visual inspection of occipital hypoperfusion had sensitivity, specificity, and accuracy values of 100%, 73.2% and 89.1%, respectively, for differentiating MCI-LB and MCI-AD. Occipital hypoperfusion was offered higher diagnostic utility than the CIS. Conclusions The occipital lobe was the region with significantly decreased rCBF in MCI-LB compared with MCI-AD subjects. Occipital hypoperfusion on brain perfusion SPECT may be a more useful imaging biomarker than the CIS for visually differentiating MCI-LB and MCI-AD.

    2024JAPANESE JOURNAL OF RADIOLOGY(2024)引用:9
    引用
    AI阅读
    加入学术空间
    4Distal Aortic Events Following Emergent Aortic Repair for Acute DeBakey Type I Aortic Dissection: an Inverse Probability of Treatment Weighting Analysis
    Shunsuke Miyahara,Gaku Uchino,Yoshikatsu Nomura,Hiroshi Tanaka,Hirohisa Murakami

    The goal of this study is to examine early and midterm results after surgical treatment of acute DeBakey type I aortic dissection (AIAD) and the effect of the range of aortic arch replacement on overall survival and prevention of distal aortic events.Between March 2002 and July 2020, a total of 374 AIAD aortic repairs were reviewed. A total of 154 (41.2%) patients had total arch replacement (TAR), whereas 220 (58.8%) had hemi- or partial arch replacement (PAR).Operative mortality did not show a significant difference (7.7% in PAR, 13.0% in TAR, p = 0.096). Survival at 5 years showed no difference (77.8% in TAR, 72.6% in PAR, p = 0.14). Freedom from reoperations and reinterventions, as well as composite aortic events in the distal aorta, were comparable across groups (p = 0.21, 0.84, and 0.91, respectively). The inverse probability of treatment weighting-adjusted model displayed higher 5-year freedom from reoperations and aortic events in the TAR group (p = 0.029 and 0.054, respectively).The extent of arch replacement is determined based on the patient background, making it difficult to compare the superiority of both surgical methods. However, TAR for appropriately selected patients may provide the benefit of avoiding aortic events in the long term.

    2024The Thoracic and cardiovascular surgeon(2024)引用:1
    引用
    AI阅读
    加入学术空间
    5Bioprosthetic Valve Positions in Patients with Atrial Fibrillation ― Insights from the BPV-AF Registry ―
    Yuki Obayashi,Makoto Miyake,Misa Takegami,Masashi Amano,Takeshi Kitai,Tomoyuki Fujita,Tadaaki Koyama,Hidekazu Tanaka,Kenji Ando,Tatsuhiko Komiya,Masaki Izumo,Hiroya Kawai,

    Background: Data on the impact of valve position on clinical outcomes in patients with atrial fibrillation (AF) and bioprosthetic valves (BPVs) are limited. Methods and Results: The BPV-AF Registry was a multicenter, prospective, observational study involving 894 patients with BPVs and AF. In this post-hoc substudy, patients were classified according to BPV position: aortic (n=588; 65.8%), mitral (n=195; 21.8%), or both (n=111; 12.4%). The primary outcome was a composite of stroke/systemic embolism, major bleeding, heart failure requiring hospitalization, all-cause death, or BPV reoperation. During a mean follow up of 15.3 +/- 4.0 months, the primary outcome occurred in 90 (15.3%) patients (12.7/100 patient-years) in the aortic group, 25 (12.8%; 10.2/100 patient-years) in the mitral group, and 16 (14.4%; 11.8/100 patient-years) in the both-valves group (log-rank P=0.621). The unadjusted and adjusted risks were not significant for the mitral and both-valves groups relative to the aortic group (unadjusted hazard ratio [95% confidence interval] 0.80 [0.52-1.25] and 0.92 [0.54-1.57]; adjusted hazard ratio 0.89 [0.51-1.54] and 1.10 [0.58-2.09], respectively). There was no significant difference in the incidence of stroke/systemic embolism or major bleeding among the 3 groups (log-rank P=0.651 and 0.156, respectively). Conclusions: In patients with BPVs and AF, the risk for the composite outcome was comparable regardless of the BPV position.

    2024CIRCULATION REPORTS(2024)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 602 篇论文

    合作机构(100)

    神户大学合作论文 89
    国立脑心血管中心合作论文 32
    Kobe City Medical Center General Hospital合作论文 21
    大阪大学合作论文 13
    东京大学合作论文 13
    筑波大学合作论文 13
    京都大学合作论文 13
    东邦大学合作论文 12
    大阪府済生会中津病院合作论文 11
    Kobe University Hospital合作论文 11

    机构统计